Author:
Gescher Andreas,Tsang Lincoln L. H.,Slack John A.
Reference16 articles.
1. A. Gescher and M.D. Threadgill, The metabolism of triazene antitumor drugs, Pharmac. Ther. 32: 191 (1987).
2. C.M.T. Horgan and M.J. Tisdale, Antitumour imidazotetrazines. IV. An investigation into the mechanism of antitmumour activity of a novel and potent antitumour agent, mitozolomide. Biochem. Pharmacol. 33: 2185 (1984).
3. K.R. Horspool, C.P. Quarterman, J.A. Slack, A. Gescher, M.F.G. Stevens and E. Lunt, Metabolic activation and murine pharmacokinetics of the 8-(N,N-dimethylcarboxamide) analog of the experimental antitumor drug mitozolomide (NSC353451), Cancer Res., 49: 5023 (1989).
4. R. Preussman and A. von Hodenberg, Mechanism of carcinogensis of 1-aryl-3,3-dialkyltriazenes. Enzymatic dealkylation by rat liver microsomal fraction in vitro, Biochem. Pharmacol. 18: 1 (1969).
5. P. Farina, A. Gescher, J.A. Hickman, J.K. Horton, M. D’Incaici, D. Ross, M.F.G. Stevens and L.C. Torti, Studies of the mode of action of antitumour triazenes and triazines. IV. The metabolism of 1-(4-acetylphenyl)-3,3-dimethgyltriazene. Biochem. Pharmacol. 31: 1887 (1982).